There is some renewed interest in GIP-based drugs, especially when co-administered with GLP-1 (GIP/GLP-1 co-agonists) with studies suggesting that both GIP agonism and GIP antagonism may facilitate weight loss in type 2 diabetes. This evidence concerns the gene GCG and type 2 diabetes mellitus.